Fennec Pharmaceuticals announces an investigator-sponsored study with City of Hope to evaluate PEDMARK for reducing cisplatin-induced ototoxicity in adult men with metastatic testicular germ cell tumors.
City of Hope's initiative addresses the growing clinical interest in preventing hearing loss among patients undergoing cisplatin-based chemotherapy.
The study aims to understand how hearing protection can enhance comprehensive cancer care and survivorship.
Clinical Interest in Hearing Protection
The collaboration reflects the rising concern for addressing hearing loss in patients treated with cisplatin-based chemotherapy.
Impact on Quality of Life
Up to 90% of patients treated with cisplatin may develop permanent hearing loss, affecting speech, education, and social well-being.
PEDMARK Potential
PEDMARK is recognized for reducing ototoxicity in pediatric patients and holds promise for adult men with metastatic testicular germ cell tumors.
- Cisplatin-induced hearing loss is a common issue affecting cancer survivors, highlighting the need for innovative solutions like PEDMARK.
- The study by City of Hope and Fennec Pharmaceuticals aims to contribute to improving oncological care and survivorship outcomes.
The collaboration between Fennec and City of Hope signifies a step towards addressing the long-term impact of cisplatin chemotherapy on patients' quality of life. The study has the potential to enhance survivorship in individuals with metastatic testicular germ cell tumors.